Inhaled Nitric Oxide Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)

Inhaled Nitric Oxide Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)

The inhaled nitric oxide market is anticipated to register a CAGR of nearly 4.6%, during the forecast period.

• Certain factors that are driving the market growth include rising prevalence of respiratory and other associated diseases and ongoing research and development activities.
• Inhaled nitric oxide (iNO) is a pulmonary vasodilator that plays a major role in regulating vascular muscle tone. Since the acknowledgment of nitric oxide (NO) as a key endothelial-derived vasodilator molecule in the last century, the field of NO research has expanded to encompass several areas of biomedical research. At present, it is well established that NO is an important signaling molecule throughout the body.
• Recent data suggest that inhaled NO can be applied in a wide variety of diseases. For instance, studies indicate that inhaled NO is a safe and effective agent to determine the vasodilatory capacity of the pulmonary vascular bed.
• Current evidence also shows that iNO improves oxygenation and decreases the combined outcome of death or necessity for extracorporeal membrane oxygenation in infants of more than 35 weeks’ gestational age at birth. Owing to all the aforementioned factors, the market is expected to observe steady growth over the forecast period.

· The American Academy of Allergy Asthma and Immunology (AAAI) states that, in 2016, approximately 8.3% of children in United States was found to have asthma. Boys were to some extent more likely to have asthma than girls at a rate of 9.2% and 7.4%, respectively.

· Asthma incidence among children increased from 8.7% in 2001 to 9.4% in 2010, and then declined to 8.3% in 2016. Although not all changes were statistically noteworthy, a similar outline was observed among subdemographic groups studied, except the Mexican/Mexican-American children, among whom asthma prevalence increased from 5.1% in 2001 to 6.5% in 2016.

· According to the CDC, during 2013–2017, an estimated 2.4 million (2.2%) US working adults aged more than 18 years who never smoked had COPD. The highest COPD prevalences among persons who never smoked were in the information (3.3%) and mining (3.1%) industries and office and administrative support occupation workers (3.3%). Women had higher COPD prevalences than did men.

· Moreover, as per the 2019 report published by the Global Initiative for Chronic Obstructive Lung Disease (GOLD), 65 million people suffer from chronic obstructive pulmonary disease (COPD) and 3 million die from it each year, making it the third leading cause of death worldwide.

· According to a 2020 article by Matthew Diamond, estimates of the incidence of ARDS in United States range from 64.2 to 78.9 cases/100,000 person-years. 25% of ARDS cases are initially classified as mild and 75% as moderate or severe. However, a third of the mild cases go on to progress to moderate or severe disease.

· In addition, asthma prevalence was highest among workers in the healthcare and social assistance industry, with 8.8% of workers stating that they had asthma at the time of the survey.

· The source also states that participants in the educational services industry reported the second-highest rate of asthma at 8.2%. Hence, the growing prevalence of respiratory diseases is expected to contribute to the significant market share of North America over the forecast period.

The market is competitive and consists of a number of players. In February 2020, Bellerophon Therapeutics announced positive topline data from the phase 2b study of INOpulse (pulsed, inhaled nitric oxide) delivery system for the treatment of pulmonary hypertension associated with pulmonary fibrosis (PH-PF). Companies like Air Liquide Healthcare, Mallinckrodt, Matheson Tri-Gas Inc., Merck KGaA, Novoteris, Nu-Med Plus, Perma Pure LLC, Praxair Technology Inc., hold the substantial market share in the market.

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support